The substance 3-fluoro-5-((7-(methylsulfonyl)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile is released as a dual oral–parenteral pharmaceutical-grade active pharmaceutical ingredient under a control strategy that separates solid oral and injectable requirements at the release point. The molecular formula is C₁₇H₁₂FNO₄S, corresponding to a nominal mole mass of 345.35 g mol⁻¹. The structure contains a fluorinated cyanophenoxy ether attached to a 2,3-dihydro-1H-inden-1-one core carrying a 7-methylsulfonyl substituent. The electron-withdrawing nitrile and methylsulfonyl groups generate a dipolar aromatic surface, while the indanone carbonyl provides a hydrogen-bond acceptor that is relevant to crystallisation and to wet-granulation solvent selection. Because no harmonised pharmacopoeial monograph for this exact structure is publicly established, the release specification is developed using ICH Q6A and ICH Q7 principles and is expected to be validated against the intended oral tablet, capsule, granule, and parenteral finished-product processes.

The product is supplied under the internal grade designation “Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable” rather than an official pharmacopoeial short name. For tablet and capsule manufacture, the API is usually processed as a micronized or contained-milled powder with a laser-diffraction particle-size specification. The oral grade is released against optical microscopy and chromatographic purity, residual solvent limits, and water content. The injectable grade carries additional controls for bacterial endotoxin, particulate matter, and container–closure simulation. The difference from less demanding nitrile-bearing intermediates is not the chemical identity but the route-specific acceptance corridor: injectable release requires endotoxin limits such as USP <85>, particulate matter testing under USP <788>, and terminal sterility or aseptic filtration compatibility. These controls are not optional for oral grades and therefore are removed from the oral release certificate only after a documented risk assessment.

Which Release Specification Controls Oral and Parenteral Grades Simultaneously?

Because the same chemical entity is used for oral and injectable finished dosage forms, the specification is a branched monograph rather than two separate products. Chromatographic purity is measured by gradient reversed-phase HPLC with UV detection; the method is validated according to ICH Q2(R2) and reviewed against USP <621> system suitability. For a dual-grade API, total related substances are typically controlled at not more than 1.0% and unspecified impurities at not more than 0.10% area by HPLC on the dried basis. Published data for this specific configuration is limited, so these thresholds must be justified by batch data from the commercial synthetic route and by the dosing frequency used in the indicated routes. Assay acceptance is ordinarily set at 98.0–102.0% on the dried basis under Q6A decision tree conventions.

The control matrix below is indicative for a parenteral-grade release when the same API is intended for solution injection. Solid oral grades delete the endotoxin and particulate-matter rows unless the tablet or granule is being used to prepare a sterile dosage form.

Residual solvent control follows ICH Q3C class limit options; methylsulfonyl-containing intermediates may require monitoring for methyl ethyl ketone, dichloromethane, or ethyl acetate depending on the final four synthetic steps. The exact solvent list is derived from the route, not from the pharmacopoeia, and is confirmed by headspace gas chromatography. Elemental impurities are handled under ICH Q3D risk assessment rather than the older heavy-metals limit test; the oral and parenteral routes share the same permitted daily exposure values, but parenteral administration often requires lower reported limits for chromium, nickel, and molybdenum if the manufacturing train uses stainless steel at all stages.

Dry granulation by roller compaction is usually the preferred solid-dosage route when the API shows acceptable compactability but poor flow after micronization. A typical roller compactor configuration for this class of API operates at roll pressures between 4 MPa and 8 MPa, a roll gap of 1.5 mm to 2.5 mm, and an integrated screening mill with mesh sizes from 0.8 mm to 1.2 mm. The compact is then blended with extragranular filler and disintegrant. If the formulation uses microcrystalline cellulose and croscarmellose sodium, the granule fraction is held at 60–75% of the total tablet weight to preserve dissolution while preventing segregation. Direct compression of the micronized API at doses above 25 mg often creates feed-frame starvation and weight variability on rotary tablet presses; therefore, a granulation step is introduced when the drug load exceeds 12% w/w or when the blend flow function coefficient falls below 4.

Ribbon density is monitored after roller compaction because ribbon thickness variability of more than ±0.2 mm at constant roll gap can shift the granule particle-size distribution and alter tablet weight control on high-speed presses. A loss-in-weight feeder controls powder delivery to the compactor; if feed flow is unstable, the roller compactor produces ribbons with density gradients across the width. Those density gradients survive milling and cause content non-uniformity in tablets at low drug load. Process analytical technology using near-infrared monitoring at the compactor outlet has been used for similar aromatic nitriles to reject ribbon portions with density outside the 90–110% target; for this API, the NIR calibration must be route-specific because the nitrile band overlaps with common tablet filler absorbances.

Capsule filling presents a separate bottleneck. Dosator-type capsule machines require plug formation and retention in the dosator tube; low-density micronized API with high interparticle cohesion can increase plug ejection force and cause capsule weight variability beyond ±5%. Tamping-pin filling is often more tolerant of cohesive API–lactose blends, but the tamping settings must be adjusted when the API mass fraction exceeds 20%. Powder-in-capsule development with this compound therefore includes bulk density, tapped density, Carr index, and shear cell flow tests. If the Carr index exceeds 25, dry granulation is substituted before encapsulation.

For granule dosage forms, the same dry-granulation route is screened to a coarser target, often 10–30 mesh, to improve flow into stick-pack and sachet filling lines. If the granule is intended for reconstitution as an oral suspension, the API particle size is reduced further and the dry granule is blended with a suspending agent such as xanthan gum and a preservative system. The preservative compatibility of the methylsulfonyl–nitrile structure is not assumed; challenge testing is performed according to USP <51> and the finished suspension is checked for nitrile hydrolysis under the pH and temperature conditions of the reconstituted product.

Particle-Size Specifications and Milling Across Solid Oral and Parenteral Operations

Particle-size control is route-dependent. For tablets and granules, a laser-diffraction D₉₀ of 15–25 µm is often sufficient to balance content uniformity and disintegration; for suspension injections, a D₉₀ below 10 µm may be required to reduce syringeability and to maintain uniform suspension during aseptic filling. Jet milling of the API through a spiral jet mill with compressed nitrogen at 0.6–0.8 MPa is used when the particle-size target cannot be achieved by pin milling without producing amorphous domains. Because amorphous domains alter dissolution and may reduce physical stability, the milled powder is checked by modulated differential scanning calorimetry and X-ray powder diffraction to confirm that the indanone carbonyl crystallinity is retained.

When Tablet Wet Granulation Is Replaced by Dry Granulation for this Aromatic Nitrile Ether

Wet granulation is avoided when the binder solvent can hydrolyse the nitrile or when the methylsulfonyl group is shown to promote solvate formation. If an aqueous binder is used, pH is maintained below 6.5 and processing time is limited because the indanone carbonyl can catalyse nitrile hydration at temperatures above 50 °C under alkaline conditions. Published data for this specific configuration is limited, so forced-degradation studies at 40 °C/75% RH and 60 °C in the selected binder system are required before wet granulation is accepted. Dry granulation avoids that degradation route but can generate overlubrication if magnesium stearate is blended for more than 5 min, producing a compact tensile strength reduction of more than 20% compared with an unlubricated control. The process is therefore designed with preshearing ratios and total blend revolutions tracked on an instrumented tumble blender.

Injectable manufacture of this API as a solution requires solubility mapping across physiological pH buffers. The fluorinated benzonitrile and methylsulfonyl moieties do not provide a strong ionisable centre for pH adjustment; the indanone ketone and nitrile are polar but not readily protonated in the parenteral range. If solubility is insufficient for a solution product, a suspension injection with poloxamer or polysorbate may be assessed, but the surfactant grade must be low-peroxide and free from amine impurities to avoid interaction with the electron-poor aromatic ring. Terminal moist-heat sterilisation at 121 °C for 15 min is tested only after the pH–temperature degradation profile is established; if subvisible particles rise above USP <788> limits, aseptic filtration through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane is selected. Membrane adsorption studies with the drug solution are mandatory because nitrogen-containing aromatics can adsorb to nylon and to certain regenerated cellulose membranes. Filterability is measured by V_max or constant-pressure throughput tests; the acceptance throughput is set by filter manufacturer data and product-specific V_max rather than by a universal value.

The main difference from simpler benzonitrile APIs is the presence of the 2,3-dihydro-1H-inden-1-one carbonyl and the methylsulfonyl group. These groups increase molecular weight to 345.35 g mol⁻¹ and introduce an additional crystalline lattice constraint that can reduce hydrate formation relative to hydroxylated benzonitrile derivatives. Unlike many early benzonitrile intermediates, this API is controlled as a finished drug substance, not as a synthetic intermediate, so residual solvents and elemental impurities are managed under ICH Q3C and ICH Q3D rather than internal reaction-window limits. The dual oral–parenteral grade differs from a simple oral-grade nitrile by the mandatory endotoxin and particulate-matter controls, by the need for sterilising-grade filter compatibility, and by the exclusion of many tablet-orientated excipients from the injectable formulation.

If the parenteral product is a suspension rather than a solution, wet milling or high-pressure homogenization is performed under nitrogen blanketing to reduce oxidation. The mean particle size after milling may be set at 0.8–1.5 µm to avoid capillary block and to maintain depot release; this requirement demands that the API has acceptable chemical stability under high shear and that no residual metal particles are introduced from the milling beads. Laser diffraction and photon correlation spectroscopy are used to track the size distribution, while X-ray powder diffraction is used to confirm that the crystalline form is unchanged. Published data specific to this chemical entity is limited, so the milling conditions are qualified for each batch size and container closure.

For lyophilized injection, the API is first dissolved or suspended in a crystalline bulking agent such as mannitol; the primary drying shelf temperature is set below the collapse temperature determined by freeze-drying microscopy. If the API is present at a low concentration in an amorphous sucrose matrix, the nitrile stretch in the solid-state Fourier-transform infrared spectrum near 2200–2250 cm⁻¹ is used to confirm chemical integrity after drying. Published data for this specific configuration is limited, so the lyophilisation cycle is based on formulation-specific differential scanning calorimetry and freeze-drying microscopy rather than the API alone.